<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00185094</url>
  </required_header>
  <id_info>
    <org_study_id>866-440</org_study_id>
    <nct_id>NCT00185094</nct_id>
  </id_info>
  <brief_title>A Comparison of the Effect of Olmesartan Medoxomil, Losartan Potassium, and Atenolol on the Ability of Overweight Patients With High Blood Pressure to Respond to Insulin</brief_title>
  <official_title>The Effects of Olmesartan Medoxomil, Losartan Potassium, and Atenolol on Insulin Sensitivity in Overweight and Obese Subjects With Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <brief_summary>
    <textblock>
      To examine the effect of three different blood pressure medications on the insulin
      sensitivity in overweight patients with high blood pressure.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2004</start_date>
  <completion_date>July 2005</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the treatment effect of olmesartan medoxomil versus that of atenolol on insulin sensitivity</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>-To compare the treatment effect of losartan potassium versus atenolol on insulin sensitivity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>-To compare the treatment effect of olmesartan medoxomil versus losartan potassium on insulin sensitivity</measure>
  </secondary_outcome>
  <enrollment>60</enrollment>
  <condition>Hypertension</condition>
  <condition>Insulin Resistance</condition>
  <condition>Metabolic Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olmesartan medoxomil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan potassium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atenolol</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients between the ages of 18 and 75 years (inclusive)

          -  Willingness to undergo insulin clamp procedure twice

          -  Overweight or obese (BMI=25-39 kg/m2)

          -  Subject must meet one of the following two blood pressure criteria at week-2 and at
             week-1: Systolic blood pressure 140-179 mmHg and diastolic blood pressure 85-99 mmHg
             OR Systolic blood pressure &lt; 140 mmHg and diastolic blood pressure 90-99 mmHg

          -  If female, must have negative serum pregnancy test at screening and be either
             post-menopausal, had a hysterectomy or tubal ligation at least 6 months before consent
             or if of childbearing potential, must practice approved measures of birth control
             throughout study

        Exclusion Criteria:

          -  Systolic blood pressure &gt; 179 mmHg

          -  Diastolic blood pressure &gt; 99 mmHg or &lt; 85 mmHg

          -  Diagnosis of diabetes mellitus

          -  History of myocardial infraction, percutaneous transluminal coronary
             revascularization, coronary artery bypass graft, unstable angina pectoris or an
             episode of heart failure requiring hospitalization

          -  Previous history of a cerebrovascular accident or a transient ischemic attack

          -  History of allergic response to atenolol, losartan potassium, olmesartan medoxomil or
             any of their components

          -  Any serious disorder, including pulmonary, hepatic, renal, gastrointestinal (including
             clinically significant malabsorption), uncontrolled endocrine/metabolic,
             hematologic/oncologic (within the last 5 years), neurologic, and psychiatric diseases,
             that would interfere with the conduct of the study or interpretation of the data

          -  Laboratory abnormalities that could compromise subject safety
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>December 22, 2005</last_update_submitted>
  <last_update_submitted_qc>December 22, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2005</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Overweight</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Atenolol</mesh_term>
    <mesh_term>Olmesartan</mesh_term>
    <mesh_term>Olmesartan Medoxomil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

